Two new-generation eye drops for dry eye

This study aims to evaluate two new-generation eye drops for adults with dry eye symptoms and assess their effects on eye comfort, tear quality, and the surface of the eye.

Woman rubbing eye

What's involved?

Taking part involves using study eye drops over an eight-week period and attending up to four visits at the University of Auckland Eye Clinic in Grafton.

  • attend up to four clinic visits over eight weeks
  • spend approximately 45 minutes at each visit
  • use study eye drops provided at no cost
  • complete questionnaires about your dry eye symptoms and eye comfort
  • have assessments of your tears and eye surface
  • record your eye drop use in a diary throughout the study

Participants may receive up to $200 in vouchers as a thank you for taking part.

Eligibility criteria

To participate, you must:

  • be aged 18 years or older
  • have experienced dry eye symptoms for at least six months
  • be willing and able to follow the study instructions
  • have a dry eye diagnosis that meets the study criteria

Who may not be eligible?

You may not be able to take part if you:

  • have severe dry eye disease
  • wear contact lenses during the study period
  • are currently using other eye medications or treatments that may affect the study results
  • have had eye surgery within the past six months
  • have active eye allergies, eye infections, or certain eye conditions
  • have received specialist dry eye treatments within the past 12 months
  • have a medical condition that may affect your safety or the study results
  • are unable to attend study visits or commit to the eight-week study period

The research team will confirm your eligibility during the screening process.

Contact details

For more information about this study or to take part, please contact:

Dr Kalika Bandamwar
Lead Investigator
Email: kalika.bandamwar@auckland.ac.nz

Professor Jennifer P. Craig
Principal Investigator
Email: jp.craig@auckland.ac.nz

Further information

This study has been approved by the Central Health and Disability Ethics Committee on 26 September 2025. Reference: 2025 EXP 23510.